The Entropy Perspective on Human Illness and Aging

Cognitive protection and brain entropy changes from omega-3 polyunsaturated fatty acids supplement in late-life depression: A 52-week randomized controlled trial

BACKGROUND

Late-life depression (LLD) is associated with risk of dementia, yet intervention of LLD provides an opportunity to attenuate subsequent cognitive decline. Omega-3 polyunsaturated fatty acids (PUFAs) supplement is a potential intervention due to their beneficial effect in depressive symptoms and cognitive function. To explore the underlying neural mechanism, we used resting-state functional MRI (rs-fMRI) before and after omega-3 PUFAs supplement in older adults with LLD.

METHODS

A 52-week double-blind randomized controlled trial was conducted. We used multi-scale sample entropy to analyze rs-fMRI data. Comprehensive cognitive tests and inflammatory markers were collected to correlate with brain entropy changes.

RESULTS

A total of 20 patients completed the trial with 11 under omega-3 PUFAs and nine under placebo. While no significant global cognitive improvement was observed, a marginal enhancement in processing speed was noted in the omega-3 PUFAs group. Importantly, participants receiving omega-3 PUFAs exhibited decreased brain entropy in left posterior cingulate gyrus (PCG), multiple visual areas, the orbital part of the right middle frontal gyrus, and the left Rolandic operculum. The brain entropy changes of the PCG in the omega-3 PUFAs group correlated with improvement of language function and attenuation of interleukin-6 levels.

LIMITATIONS

Sample size is small with only marginal clinical effect.

CONCLUSION

These findings suggest that omega-3 PUFAs supplement may mitigate cognitive decline in LLD through anti-inflammatory mechanisms and modulation of brain entropy. Larger clinical trials are warranted to validate the potential therapeutic implications of omega-3 PUFAs for deterring cognitive decline in patients with late-life depression.

Network topologies for maximal organismal health span and lifespan

The population dynamics of human health and mortality can be jointly captured by complex network models using scale-free network topology. To validate and understand the choice of scale-free networks, we investigate which network topologies maximize either lifespan or health span. Using the Generic Network Model (GNM) of organismal aging, we find that both health span and lifespan are maximized with a "star" motif. Furthermore, these optimized topologies exhibit maximal lifespans that are not far above the maximal observed human lifespan. To approximate the complexity requirements of the underlying physiological function, we then constrain network entropies. Using non-parametric stochastic optimization of network structure, we find that disassortative scale-free networks exhibit the best of both lifespan and health span. Parametric optimization of scale-free networks behaves similarly. We further find that higher maximum connectivity and lower minimum connectivity networks enhance both maximal lifespans and health spans by allowing for more disassortative networks. Our results validate the scale-free network assumption of the GNM and indicate the importance of disassortativity in preserving health and longevity in the face of damage propagation during aging. Our results highlight the advantages provided by disassortative scale-free networks in biological organisms and subsystems.